Platelet Drop After IV Iron Reveals How Much Iron Reaches the Failing Heart

Iron deficiency (ID) affects a large proportion of heart failure (HF) patients and worsens outcomes. Intravenous ferric carboxymaltose (FCM) is an established therapy, but clinicians currently lack a simple blood-based tool to monitor whether administered iron is actually reaching the myocardium. This study explored whether post-FCM changes in platelet count could serve that role.

The research was a post-hoc analysis of the Myocardial-IRON trial, a double-blind, randomized, placebo-controlled study (NCT03398681). Of 53 original participants, 45 outpatients with HF and reduced or mildly reduced ejection fraction (<50%) and confirmed ID were included (25 FCM, 20 placebo). The mean age was 71 years, 71% were male, and baseline platelet counts averaged 210 × 10⁹/L. Platelet counts were measured at baseline, 7 days, and 30 days. Cardiac MRI was performed at the same time points to assess native T1-mapping (a surrogate for myocardial iron content—lower T1 values indicate more iron deposition) and 3D global longitudinal strain (CMR-GLS) as a measure of left ventricular systolic function.

At 30 days, FCM-treated patients showed a statistically significant reduction in platelet count compared to placebo (p = 0.027), consistent with prior reports of thrombocytopenia following IV iron. The key novel finding was the direction of the relationship: within the FCM group, patients who experienced a greater 30-day platelet count reduction showed smaller decreases in T1-mapping values (p = 0.024), meaning less iron was deposited in the myocardium. They also showed smaller improvements in CMR-GLS (p = 0.028), indicating less functional cardiac benefit. This suggests that a more pronounced platelet drop may reflect iron being captured by platelets or the reticuloendothelial system rather than delivered to cardiac tissue.

The proposed mechanism centers on iron's known role in thrombopoiesis. Platelets are rich in iron-containing proteins and megakaryocyte maturation is iron-dependent. When systemic iron rises sharply after FCM infusion, iron may be preferentially taken up by platelet precursors or other rapidly proliferating cells, effectively competing with cardiomyocytes for the newly available iron. A larger platelet drop could therefore be a surrogate marker of suboptimal myocardial iron delivery.

These findings raise the possibility that serial platelet counts—a routine, inexpensive, and widely available laboratory test—could be used to stratify HF patients by degree of myocardial iron repletion after FCM, potentially guiding re-dosing decisions or identifying non-responders. However, the analysis is hypothesis-generating given its post-hoc, small-sample nature, and prospective validation is needed before clinical implementation.